by Damon Race | Mar 26, 2024 | In the News
ReciBioPharm, GeneVentiv to advance GENV-HEM to Phase 1/2 clinical testing by Margarida Maia, PhD | March 15, 2024 ReciBioPharm and GeneVentiv Therapeutics are teaming up to advance the development of GENV-HEM, a gene therapy for all hemophilia patients, including...
by Damon Race | Mar 13, 2024 | Press
March 13 2024 ReciBioPharm, the advanced and emerging therapies business unit of Recipharm, has announced a collaboration agreement with GeneVentiv Therapeutics, a pre-clinical gene therapy company, to advance development of an Adeno-Associated Virus (AAV)-based...
Recent Comments